Using a targeting ligand like angiopep attached to the outside of a lipid nanopaticle. There are papers where researchers have already done this.
Yes, probably, though I don’t think it will be particularly common. The way to avoid this is just to incorporate a bunch of predictors for other traits into your allele selection criteria.
Obviously yes, though hopefully we just wouldn’t need to flip those alleles in the first place. I’m still uncertain about the maximum effect size.
Maybe? Our predictors for the genetics of personality still aren’t very good, so it would be hard to evaluate the expected effect size.
I’m not sure what that would mean in this context. I think the first human trials would probably target polygenic brain diseases like Alzheimer’s. If the delivery platform works, you could use it to dramatically adjust someone’s polygenic risk score for many diseases. So you might as well do the first trials on people who are going to die from a degenerative brain disease with no cure or effective treatment, for which in-vivo editing might offer a solution.
I don’t know the answer to this yet. Most of the pioneering work in this field has happened in the US, so my suspicion is it would start here. Pretty much every step except perhaps the human trials could be done in the US.
I would have to think about this one more. If this tech actually works it would become incredibly valuable. Because you could use the delivery platform to basically target any disease of your choosing by adjusting someone’s polygenic risk score. There are still questions around whether you can repeatedly dose someone with the editing agent without provoking an immune response, but there are plausible solutions to all the problems I’ve looked at so far. My biggest concern though relates to AI; I really don’t want this tech to be used to speed up development of world-conquering AI. The main reason I’m interested in the tech is because I think it could potentially result in people capable of solving some of the more difficult problems in AI alignment and coordination around its appropriate use. If I were to open source it I would lose control of that.
And I think in reality there will be a lot of stakeholders in the technology so the decision won’t be mine alone. If I want to bring something like this to market, I’ll need to raise quite a bit of money and work with a lab to run animal trials. So there will be many other stakeholders with input into that decision. I suspect open-sourcing the tech would also diminish the financial gain.
8. Hard to answer, but my default assumption is they would be just like an elderly person with a very high IQ.
9. I’ll let you know when the main post goes up.
All good questions.
Using a targeting ligand like angiopep attached to the outside of a lipid nanopaticle. There are papers where researchers have already done this.
Yes, probably, though I don’t think it will be particularly common. The way to avoid this is just to incorporate a bunch of predictors for other traits into your allele selection criteria.
Obviously yes, though hopefully we just wouldn’t need to flip those alleles in the first place. I’m still uncertain about the maximum effect size.
Maybe? Our predictors for the genetics of personality still aren’t very good, so it would be hard to evaluate the expected effect size.
I’m not sure what that would mean in this context. I think the first human trials would probably target polygenic brain diseases like Alzheimer’s. If the delivery platform works, you could use it to dramatically adjust someone’s polygenic risk score for many diseases. So you might as well do the first trials on people who are going to die from a degenerative brain disease with no cure or effective treatment, for which in-vivo editing might offer a solution.
I don’t know the answer to this yet. Most of the pioneering work in this field has happened in the US, so my suspicion is it would start here. Pretty much every step except perhaps the human trials could be done in the US.
I would have to think about this one more. If this tech actually works it would become incredibly valuable. Because you could use the delivery platform to basically target any disease of your choosing by adjusting someone’s polygenic risk score. There are still questions around whether you can repeatedly dose someone with the editing agent without provoking an immune response, but there are plausible solutions to all the problems I’ve looked at so far. My biggest concern though relates to AI; I really don’t want this tech to be used to speed up development of world-conquering AI. The main reason I’m interested in the tech is because I think it could potentially result in people capable of solving some of the more difficult problems in AI alignment and coordination around its appropriate use. If I were to open source it I would lose control of that.
And I think in reality there will be a lot of stakeholders in the technology so the decision won’t be mine alone. If I want to bring something like this to market, I’ll need to raise quite a bit of money and work with a lab to run animal trials. So there will be many other stakeholders with input into that decision. I suspect open-sourcing the tech would also diminish the financial gain. 8. Hard to answer, but my default assumption is they would be just like an elderly person with a very high IQ. 9. I’ll let you know when the main post goes up.